Co-Authors
This is a "connection" page, showing publications co-authored by LEONID METELITSA and AMY COURTNEY.
Connection Strength
3.124
-
Natural killer T cells and other innate-like T?lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023 02 23; 141(8):869-876.
Score: 0.858
-
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function. Cancer Immunol Res. 2025 Apr 02; 13(4):577-590.
Score: 0.248
-
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2024 Apr; 30(4):1210.
Score: 0.232
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
Score: 0.218
-
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-a triggers tumorigenic inflammation in neuroblastoma. J Immunother Cancer. 2023 03; 11(3).
Score: 0.215
-
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells. Cancer Immunol Res. 2023 02 03; 11(2):171-183.
Score: 0.214
-
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
Score: 0.182
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
Score: 0.169
-
IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol. 2018 10 01; 201(7):2141-2153.
Score: 0.157
-
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
Score: 0.134
-
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014 Oct 30; 124(18):2824-33.
Score: 0.118
-
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025 Jan 11; 13(1).
Score: 0.061
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
Score: 0.061
-
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. Res Sq. 2024 Apr 03.
Score: 0.058
-
A Nanoradiomics Approach for Differentiation of Tumors Based on Tumor-Associated Macrophage Burden. Contrast Media Mol Imaging. 2021; 2021:6641384.
Score: 0.048
-
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320.
Score: 0.043
-
Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res. 2014 Nov 01; 74(21):6260-70.
Score: 0.030
-
G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013 Jul 01; 73(13):4134-46.
Score: 0.027
-
C-Glycosphingolipids with an exo-methylene substituent: stereocontrolled synthesis and immunostimulation of mouse and human natural killer T lymphocytes. Chembiochem. 2012 Aug 13; 13(12):1733-7.
Score: 0.026
-
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
Score: 0.025